Sam Lubner

Associate Professor of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sam Lubner is an Associate Professor of Medicine at the University of Wisconsin-Madison Carbone Cancer Center in the United States. His research areas include chemotherapy resistance in pancreatic and ampullary cancers, advanced cholangiocarcinoma, and neuroendocrine tumors, as demonstrated in his recent publications. He has contributed significantly to studies on efficacy results of targeted therapies and interventional techniques in oncology.

Articles (7)

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Maeve Lowery

Professor of Translational Cancer Medicine

Trinity College Dublin

IRELAND

View details

William L Murphy

University of Wisconsin-Madison

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sam Lubner

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

Efficacy of percutaneous image-guided biopsy for diagnosis of intrahepatic cholangiocarcinoma.

Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis.

A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.

Collaborators (2)

Maeve Lowery

William L Murphy

Make your next move.